Director Shareholding

RNS Number : 7425A

GlaxoSmithKline PLC

02 January 2018

 

GlaxoSmithKline plc (the "Company")

Director Shareholding

Further to the announcement made by the Company on 8 November 2017, in respect of the appointment of Dr Hal Barron as Chief Scientific Officer and President, R&D, and Executive Director, Dr Barron assumed his new role on 1 January 2018.

As at the date of his appointment to the Board, Dr Barron held 1,644 American Depositary Shares in the Company.

V A Whyte

Company Secretary

2 January 2018

 

END

 

 

DSHBTMJTMBAMBPP